If you’re transitioning laterally between biologic classes due to adverse effects, do you repeat the loading dose?
For instance, if a patient develops conjunctivitis on IL 4/13 inhibitor (dupiliumab) to a IL13 (Adbry, Ebyglyss), or between IL13s? Similarly, this question pertains for 17s, and 23s.
Answer from: at Academic Institution
I do usually repeat the loading dose when starting a new biologic, even if in the same class. If there is data on whether or not you should do this, I am not aware of it.
Comments
at Precision Dermatology, P.A. I think starting with a loading dose when switchin...
at Jefferson Regional Medical Center I do loading dose also.
It depends on how much psoriasis burden the patient has when making the switch. When the patient has been cleared or mostly cleared by the biologic currently about to be discontinued, I will go onto maintenance dose with the next. If the patient has not responded well to the current treatment to be ...
I think starting with a loading dose when switchin...
I do loading dose also.